United States v. George Naum, III

Court of Appeals for the Fourth Circuit·Decided April 11, 2025·No. 20-4133·Unpublished

Opinion

Certiorari granted by Supreme Court, June 30, 2022 Vacated and remanded by Supreme Court, June 30, 2022

UNPUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 20-4133

UNITED STATES OF AMERICA, Plaintiff - Appellee,

v. GEORGE P. NAUM, III, Defendant - Appellant.

Appeal from the United States District Court for the Northern District of West Virginia, at Clarksburg. Irene M. Keeley, Senior District Judge. (1:18-cr-00001-IMK-MJA-2)

Submitted: September 10, 2020 Decided: October 13, 2020

Before MOTZ, HARRIS, and QUATTLEBAUM, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Elgine H. McArdle, MCARDLE LAW OFFICES, Wheeling, West Virginia, for Appellant. William J. Powell, United States Attorney, Wheeling, West Virginia, Sarah E. Wagner, Assistant United States Attorney, OFFICE OF THE UNITED STATES ATTORNEY, Clarksburg, West Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

George P. Naum, III, appeals from his convictions and sentence following his jury trial. Naum was convicted of conspiracy to distribute suboxone outside the bounds of professional medical practice between 2008 and 2016, in violation of 21 U.S.C. § 841(a)(1) and 21 U.S.C. § 846, and four counts of aiding and abetting the distribution of suboxone outside the bounds of professional medical practice in violation of 21 U.S.C. § 841(a) and 18 U.S.C. § 2. The district court sentenced Naum to six months incarceration followed by six months of home detention. In addition, the district court imposed a forfeiture order of $77,063.00. After careful consideration of Naum’s numerous claims on appeal, we affirm.

I.

These charges arose from Naum’s involvement in a Weirton, West Virginia suboxone clinic known as Advance Healthcare (“Advance”), which was owned and operated by Sharon Jackson and co-defendant Eric Drake, and which also employed co-defendant Dr. Felix Brizuela. The evidence at trial viewed in the light most favorable to the Government was as follows.

Advance was a suboxone clinic that offered its patients office-based addiction treatment. Jackson, a registered nurse, and Drake, an individual with no medical training, ran the day-to-day operations of Advance. Advance employed Naum and Brizuela, who were both authorized to prescribe suboxone to treat drug addiction. Naum and Brizuela were scheduled to be at Advance just one evening each a week, and when they were not present, Jackson used their authority pursuant to their “DEA numbers” to issue prescriptions for suboxone to Advance’s patients.

Naum and Brizuela allowed Jackson nearly unfettered use of their DEA numbers, delegated most of the patient care to Jackson, and frequently missed all or part of their once-a-week assigned shifts at Advance. In fact, during a two-month period in 2016, footage from a pole camera placed by investigators outside the clinic revealed that Naum was present at Advance only 13.9% of the time that it was open to patients and prescriptions for suboxone were being issued from it. Jackson testified that she could not have treated patients without the doctors’ DEA numbers.

When they were present in the office, the doctors reviewed and signed off on patient charts and saw new patients. New patients were given drug screens, filled out paperwork, met with Jackson, and met with a physician if one were present. If a physician met with the patient, he told Jackson what beginning dose of suboxone to start the patient on, and she communicated the prescription to the pharmacy. If no physician was present at the initial visit, Jackson diagnosed the patient with an opioid use disorder, decided on a daily dose of suboxone, and called in the prescription using one of the doctors’ DEA numbers Jackson and Drake both testified that they had verbal agreements with Naum and Brizuela permitting Jackson to issue prescriptions under their DEA numbers to new patients who had not seen a physician, so long as she did not prescribe more than 16 milligrams per day. If she conducted the entire initial visit, Jackson scheduled the patient to come back to see one of the physicians. As a policy, Naum and Brizuela generally only saw patients on the initial visit or one visit early on in their treatment. Follow-up visits were generally only with Jackson.

In addition to making dosing decisions for new patients who had not been seen by a physician, Jackson had blanket permission from Naum and Brizuela to wean or decrease patients’ doses. Naum often wrote instructions in each patient’s medical chart to either maintain or decrease a patient’s dose, but Jackson had Naum’s permission to disregard those written instructions based on the conversations she was having with patients. Naum never confronted Jackson about overriding his written instructions by prescribing different doses to his patients.

The Government’s expert, Dr. Patrick Marshalek, testified about medical standards to which physicians who prescribe controlled substances to treat addiction must adhere. He testified that many of those standards were promulgated by the Substance Abuse and Mental Health Services Administration (SAMHSA). Marshalek testified that physicians must maintain an ongoing relationship with patients to whom they prescribe controlled substances that extends beyond the initial examination and diagnosis. There is a time after which a doctor-patient relationship expires and must be renewed by another face-to-face visit in order to continue issuing prescriptions for controlled substances. Marshalek testified that the rules of the West Virginia Board of Osteopathic Medicine (WVBOM) 1 require physicians to make an in-person examination of patients to whom they are prescribing controlled substances no less than once every six months for the duration of their treatment. See W. Va. C.S.R. § 24-1-18.2.a.5.

1

The WVBOM oversees the licensing of osteopathic physicians like Naum and Brizuela in West Virginia.

The WVBOM also prohibits physicians from delegating responsibilities to others who are not qualified to carry them out. See W. Va. C.S.R. § 24-1-18.1.aa. Marshalek testified that physicians who prescribe controlled substances to patients may not delegate their prescriptive authority to others who do not themselves have such authority. Physicians may not delegate the decision as to dose or medication to a nurse, and they may not authorize nurses to override their instructions as to dosages or medication. Physicians must also evaluate patients’ continued need for medication in an ongoing manner. The prohibition against delegating the responsibility to prescribe suboxone to non-authorized individuals, including nurses, is expressly explained in the SAMHSA Guidelines. Marshalek also testified that it is the physician, and not a nurse, who must diagnose a patient with an opioid use disorder. Marshalek reviewed the charts of the patients who received the prescriptions charged in the indictment and opined that each prescription was issued outside the bounds of medicine.

The Government also introduced the testimony of Cpl. J.W. Smith, who in an undercover capacity, posed as a patient at Advance, as well as various actual patients. These witnesses testified to either brief examinations by Naum or no examination at all. Some patients had never met with Naum and/or did not realize he was their doctor. In addition, there were instances where Jackson weaned the patient where Naum instructed Jackson to continue the present dose or continued the present dose when Naum instructed her to wean. On those occasions, Naum signed off on the deviated course after the fact.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. George Naum, III, (4th Cir. 2025).

United States v. George Naum, III (United States v. George Naum, III) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Moore
423 U.S. 122 (Supreme Court, 1975)
United States v. Martin
662 F.3d 301 (Fourth Circuit, 2011)
United States v. Tran Trong Cuong, M.D.
18 F.3d 1132 (Fourth Circuit, 1994)
United States v. Jose P. Floresca
38 F.3d 706 (Fourth Circuit, 1994)
United States v. Ram Singh
54 F.3d 1182 (Fourth Circuit, 1995)
United States v. Christian Allmendinger
706 F.3d 330 (Fourth Circuit, 2013)
United States v. Jack Kelly Joseph
709 F.3d 1082 (Eleventh Circuit, 2013)
United States v. Perry
560 F.3d 246 (Fourth Circuit, 2009)
United States v. Hurwitz
459 F.3d 463 (Fourth Circuit, 2006)
United States v. Donald Blankenship
846 F.3d 663 (Fourth Circuit, 2017)
United States v. Ronald Miltier
882 F.3d 81 (Fourth Circuit, 2018)
United States v. Felix Brizuela, Jr.
962 F.3d 784 (Fourth Circuit, 2020)